Upgrade to SI Premium - Free Trial

Chardan Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT) amid FDA accelerated approval

March 27, 2026 12:00 PM
Chardan analyst Geulah Liveshits reiterated a Buy rating and $11.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT)The analyst commented, "On ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments